PT  - JOURNAL ARTICLE
AU  - Gudenkauf, Lisa M.
AU  - Chavez, Melody
AU  - Maconi, Melinda L.
AU  - Geiss, Carley
AU  - Seyedroudbari, Ameen
AU  - Thin, Pan
AU  - Hoogland, Aasha I.
AU  - Nguyen, Kathleen
AU  - Murthy, Vishnu
AU  - Armstrong, Wesley R.
AU  - Komrokji, Khaled
AU  - Oswald, Laura B.
AU  - Jim, Heather S.L.
AU  - El-Haddad, Ghassan
AU  - Fendler, Wolfgang Peter
AU  - Herrmann, Ken
AU  - Cella, David
AU  - Czernin, Johannes
AU  - Hofman, Michael S.
AU  - Dicker, Adam P.
AU  - Calais, Jeremie
AU  - Tagawa, Scott T.
AU  - Gonzalez, Brian D.
TI  - Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy
AID  - 10.2967/jnumed.122.264946
DP  - 2023 Jan 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.122.264946
4099  - http://jnm.snmjournals.org/content/early/2023/01/12/jnumed.122.264946.short
4100  - http://jnm.snmjournals.org/content/early/2023/01/12/jnumed.122.264946.full
AB  - The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly with recent FDA approval of the first Lutetium-177-PSMA-ligand. Current patient-reported outcomes (PRO) measures were designed to assess impacts of chemotherapy or surgery. We aimed to develop the first PRO measure for PC patients receiving RNT. Methods: First, we identified relevant symptoms/toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the FACT-RNT with patient input. Results: This multi-step process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) is a new standardized tool to monitor relevant symptoms/toxicities in RNT trials and real-world settings.